Open AccessPoor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center
Author(s) -
Anant Ramaswamy,
Amit Joshi,
Vanita Noronha,
Vijay Patil,
Anil Kumar Sahu,
Deepan R Manickam,
Rushabh Kothari,
Nilesh Sable,
Archi Agrawal,
Santosh Me,
Kumar Prabhash
Publication year - 2017
Publication title -
indian journal of medical and paediatric oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.229
H-Index - 22
eISSN - 0975-2129
pISSN - 0971-5851
DOI - 10.4103/ijmpo.ijmpo_154_16
Subject(s) - medicine , temsirolimus , sunitinib , mucositis , pazopanib , renal cell carcinoma , rash , sorafenib , adverse effect , oncology , surgery , radiation therapy , hepatocellular carcinoma , apoptosis , biochemistry , chemistry , protein kinase b , discovery and development of mtor inhibitors
Poor-risk advanced Renal cell carcinoma (RCC) are an under-evaluated and difficult to treat subset of patients with poor prognosis. While Temsirolimus is the approved first line therapy for this category, Tyrosine kinase inhibitors (TKIs) are also commonly uses as initial treatment. We present an analysis of poor-risk advanced RCC treated in our institute.